Literature DB >> 20157385

Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole.

Young Kyung Yoon1, Min Ja Kim, Yong Gu Chung, Il Young Shin.   

Abstract

Rhino-orbital-cerebral (ROC) mucormycosis is an uncommon, acute and aggressive fungal infection. It remains a challenging problem to clinicians despite aggressive debridement surgery and antifungal therapy. The authors describe a case of ROC mucormycosis with pericranial abscess occurring in a female patient with uncontrolled diabetes mellitus. The infection initially developed in the right-sided nasal sinus and later progressed through the paranasal sinuses with the invasion of the peri-orbital and frontotemporal region, due to the delayed diagnosis and treatment. Numerous non-septate hyphae of the zygomycetes were identified by a punch biopsy from the nasal cavity and by an open biopsy of the involved dura. The patient was treated successfully with extensive debridement of her necrotic skull and surrounding tissues, drainage of her pericranial abscess and antifungal therapy, including intravenous amphotericin B for 61 days and oral posaconazole for the following 26 days. She returned to a normal life and has had no recurrence since the end of her treatment 15 months ago.

Entities:  

Keywords:  Amphotericin B; Mucormycosis; Neurosurgery; Posaconazole

Year:  2010        PMID: 20157385      PMCID: PMC2817523          DOI: 10.3340/jkns.2010.47.1.74

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  19 in total

Review 1.  Fungal sinusitis.

Authors:  R D deShazo; K Chapin; R E Swain
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

Review 2.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

3.  Rhinocerebral mucormycosis: evolution of the disease and treatment options.

Authors:  K L Peterson; M Wang; R F Canalis; E Abemayor
Journal:  Laryngoscope       Date:  1997-07       Impact factor: 3.325

4.  Ten years' experience in zygomycosis at a tertiary care centre in India.

Authors:  A Chakrabarti; A Das; A Sharma; N Panda; S Das; K L Gupta; V Sakhuja
Journal:  J Infect       Date:  2001-05       Impact factor: 6.072

5.  Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes.

Authors:  A Bhansali; S Bhadada; A Sharma; V Suresh; A Gupta; P Singh; A Chakarbarti; R J Dash
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 6.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079

Review 8.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

9.  Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Authors:  D J Diekema; S A Messer; R J Hollis; R N Jones; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

10.  Rhinocerebral mucormycosis: predisposing factors.

Authors:  J S McNulty
Journal:  Laryngoscope       Date:  1982-10       Impact factor: 3.325

View more
  6 in total

1.  Rhino-orbital Mucormycosis Treated Successfully with Posaconazole without Exenteration.

Authors:  Jason Zhang; James D Kim; Hilary A Beaver; Masayoshi Takashima; Andrew G Lee
Journal:  Neuroophthalmology       Date:  2013-09-24

2.  Rapidly progressive rhino-orbito-cerebral mucormycosis in a patient with type 2 diabetes: A case report.

Authors:  Yan-Xia Chen; Yin-Xi He; Hong Zhou; Mian Wang; Sheng-Ou Su
Journal:  Exp Ther Med       Date:  2017-01-20       Impact factor: 2.447

Review 3.  Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.

Authors:  Asim Azhar; Wajihul Hasan Khan; Parvez Anwar Khan; Khaled Alhosaini; Mohammad Owais; Aijaz Ahmad
Journal:  J Infect Public Health       Date:  2022-02-18       Impact factor: 3.718

4.  Posaconazole treatment in Korea: single-center experience over 5 years.

Authors:  Hyo-Jin Lee; Jae-Cheol Kwon; Si-Hyun Kim; Su-Mi Choi; Dong-Gun Lee; Sun-Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Byung-Sik Cho; Seok Lee; Hee-Je Kim; Chang-Ki Min; Jong-Wook Lee; Woo-Sung Min
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

5.  Orbital mucormycosis in an immunocompetent individual.

Authors:  P Badiee; Z Jafarpour; A Alborzi; P Haddadi; M Rasuli; M Kalani
Journal:  Iran J Microbiol       Date:  2012-12

Review 6.  An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis.

Authors:  Sheri K Palejwala; Tirdad T Zangeneh; Stephen A Goldstein; G Michael Lemole
Journal:  Surg Neurol Int       Date:  2016-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.